World Health Organization site
Skip Navigation Links

Main
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Register: EUCTR
Last refreshed on: 25 September 2012
Main ID:  EUCTR2011-001437-16-DE
Date of registration: 09/02/2012
Prospective Registration: Yes
Primary sponsor: Novartis Pharma Services AG
Public title: A 3 year study to determine if optical coherence tomography can be used to measure disease progression in patients with multiple sclerosis
Scientific title: A 3-year, multi-center study to evaluate optical coherence tomography as an outcome measure in patients with multiple sclerosis -
Date of first enrolment: 19/09/2012
Target sample size: 420
Recruitment status: Authorised-recruitment may be ongoing or finished
URL:  https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2011-001437-16
Study type:  Interventional clinical trial of medicinal product
Study design:  Controlled: yes Randomised: no Open: yes Single blind: no Double blind: no Parallel group: no Cross over: no Other: yes Other trial design description: longitudinal, pharmacologically non-interventional study design If controlled, specify comparator, Other Medicinial Product: no Placebo: no Other: yes Other specify the comparator: No comparator. Study contains untreated reference subjects without ophthalmologic/neurologic disease Number of treatment arms in the trial: 0  
Phase: 
Countries of recruitment
Australia Austria Canada Czech Republic Denmark France Germany Italy
Netherlands Poland Spain Switzerland United Kingdom United States
Contacts
Name: Medical Competence Center   
Address:  Roonstr. 25 90429 Nürnberg Germany
Telephone: +49 1802 232300
Email: infoservice.novartis@novartis.com
Affiliation:  Novartis Pharma GmbH
Name: Medical Competence Center   
Address:  Roonstr. 25 90429 Nürnberg Germany
Telephone: +49 1802 232300
Email: infoservice.novartis@novartis.com
Affiliation:  Novartis Pharma GmbH
Key inclusion & exclusion criteria
Inclusion criteria:
Patients eligible for inclusion in this study have to fulfill the following criteria:
• Written informed consent must be obtained before any assessment is performed
• Male and female patients aged 18-55 years inclusive
• A diagnosis of MS as defined by the 2005 revision to the McDonald criteria with a relapsingremitting
course
• MS disease duration of more than one year (from diagnosis of MS) before study entry (Screening) Participants of the reference group eligible for inclusion have to fulfill the following criteria:
• Written informed consent must be obtained before any assessment is performed
• Male and female subjects aged 18-55 years inclusive
• Matched to MS patients recruited in terms of age (±3 years),
ethnicity, gender and visual refraction (±2 diopters) with the MS patients recruited.
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 420
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range

Exclusion criteria:
1. HIV or any other known immunodeficiency syndrome (disease or drug-induced)
2. Any ophthalmologic reason for RNFL pathology other than MS, such as: optic neuropathy, active advanced glaucoma, injury of the optic nerve based on the ophthalmologist’s clinical judgment or • history or presence of severe myopia: a. in patients who have not had refractive surgery, a refractive error of greater than 6.00 diopters b. pathologic fundus changes of high myopia, such as retinal pigmentary atrophy, besides peripapillary atrophy (atrophy involving the macula) or a staphyloma c. in patients that have had previous refractive surgery, an axial eye length of greater than 26 mm
3. Acute optic neuritis within the past 6 months before Baseline
4. Evidence of advanced, non-proliferative or proliferative diabetic retinopathy
5. Presence of retinal conditions associated with edema, subretinal fluid, cysts, etc.
6. History of a severe head trauma
7. Any of the following neurologic/psychiatric disorders:
• history of substance abuse (drug or alcohol) in the past five years or any other factor (i.e., serious psychiatric condition) that may interfere with the subject’s ability to cooperate and comply with the study procedures • specific MRI findings (tumor, subdural haematoma, post-contusional changes, territorial stroke, neurodegenerative disorders, aneurysm/arteriovenous malformation, evidence of past macroscopic haemorrhage, or other relevant MRI findings that would interfere with evaluation) • progressive neurological disorder, other than MS, which may affect participation in the study
8. Concomitant use of drugs that may directly affect retinal structure and function (e.g. chronic systemic corticosteroids [>30 consecutive days; doses higher than Cushing threshold e.g. prednisone 7.5mg/d], intraocular anti-angiogenic drugs [ranibizumab, bevacizumab], intraocular steroids etc.)
9. Any medically unstable condition, progressive disease (other than MS) or other condition that would preclude reliable participation in the study as assessed by the investigator
10. Patients unable to undergo MRI scans including gadolinium enhancement:
• reduced renal clearance (eGFR <45 ml/min) • history of severe hypersensitivity to gadolinium-DTPA • claustrophobia that cannot be overcome otherwise
11. Patients who have received an investigational drug or therapy within 30 days or 5 half lives, which ever is longer, of the baseline visit. No additional exclusions may be applied by the investigator, in order to ensure that the population will be representative of all eligible patients. Participants of the reference group fulfilling any of the following criteria are not eligible for inclusion in this study:
1. HIV or any other known immunodeficiency syndrome (disease or drug-induced)
2. Any ophthalmologic reason for RNFL pathology other than MS, such as: • optic neuropathy, active advanced glaucoma, injury of the optic nerve based on the ophthalmologist’s clinical judgment or • history or presence of severe myopia:
a. in subjects who have not had refractive surgery, a refractive error of greater than 6.00 diopters b. pathologic fundus changes of high myopia, such as retinal pigmentary atrophy, besides peripapillary atrophy (atrophy involving the macula) or a staphyloma c. in subjects that have had previous refractive surgery, an axial eye length of greater than 26 mm
3. Acute optic neuritis within the past 6 months before Baseline
4. Evidence of advanced, non-proliferative or proli


Age minimum:
Age maximum:
Gender:
Female: yes
Male: yes
Health Condition(s) or Problem(s) studied
multiple sclerosis
MedDRA version: 15.0 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders
Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Intervention(s)

Trade Name: Gilenya
Pharmaceutical Form: Capsule, hard
INN or Proposed INN: Fingolimod
CAS Number: 162359-56-0
Other descriptive name: FINGOLIMOD HYDROCHLORIDE
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 0.5-

Trade Name: Extavia
Pharmaceutical Form: Powder and solvent for solution for injection
INN or Proposed INN: Interferon beta-1b
CAS Number: 145155-23-3
Other descriptive name: INTERFERON BETA-1B
Concentration unit: µg/ml microgram(s)/millilitre
Concentration type: equal
Concentration number: 250-

Trade Name: Tysabri
Pharmaceutical Form: Concentrate for solution for infusion
INN or Proposed INN: NATALIZUMAB
CAS Number: 189261-10-7
Concentration unit: mg/ml milligram(s)/millilitre
Concentration type: equal
Concentration number: 20-

Trade Name: Copaxone
Pharmaceutical Form: Solution for injection in pre-filled syringe
INN or Proposed INN: glatiramer acetate
CAS Number: 147245-92-9
Other descriptive name: GLATIRAMER ACETATE
Concentration unit: mg/ml milligram(s)/millilitre
Concentration type: equal
Concentration number: 20-

Trade Name: Avonex
Pharmaceutical Form: Powder and solvent for solution for injection
INN or Proposed INN: Interferon beta-1a
CAS Number: 220581-49-7
Other descriptive name: INTERFERON BETA-1A
Concentration unit: µg microgram(s)
Concentration type: equal
Concentration number: 30-

Primary Outcome(s)
Main Objective: To evaluate change in RNFL thickness in RRMS patients followed for up to 36 months compared to a group of reference subjects (without neurologic or ophthalmic disease) to determine whether the optical coherence tomography (OCT) technology is sufficiently sensitive to disease and to change over time.
Primary end point(s): The primary objective of the study is to evaluate the change in RNFL thickness in MS patients followed for up to 36 months compared to a group of reference subjects (without ophthalmic
and neurologic disease).
Secondary Objective: To evaluate the correlation of change in RNFL thickness and macular volume with change in brain volume as measured by MRI in RRMS patients followed for up to 36 months.
To evaluate the correlation of change in RNFL thickness and macular volume with change in disability (as assessed by the EDSS and visual function) in RRMS patients followed for up to 36 months.
To evaluate short-team reproducibility of the RNFL thickness measure at study start by test/re-test estimation after a 4–week interval in RRMS patients and reference subjects (without neurologic or ophthalmic disease).
To evaluate short-term reproducibility (4-week interval) in macular volume measure (as above).
To evaluate change in macular volume over 36 months in RRMS patients compared to a group of reference subjects (without neurologic or ophthalmic disease).
Timepoint(s) of evaluation of this end point: 36 months
Secondary Outcome(s)
Secondary end point(s): To evaluate the correlation of change in RNFL thickness and macular volume with change in
brain volume as measured by MRI in RRMS patients followed for up to 36 months.
To evaluate the correlation of change in RNFL thickness and macular volume with change in disability (as assessed by the EDSS and visual function) in RRMS patients followed for up to
36 months.
To evaluate short-team reproducibility of the RNFL thickness measure at study start by test/re-test estimation after a 4–week interval in RRMS patients and reference subjects (without neurologic or ophthalmic disease).
To evaluate short-term reproducibility (4-week interval) in macular volume measure (as above).
To evaluate change in macular volume over 36 months in RRMS patients compared to a group of reference subjects (without neurologic or ophthalmic disease).
Timepoint(s) of evaluation of this end point: see E.5.2
Secondary ID(s)
CFTY720D2319
Source(s) of Monetary Support
Novartis Pharma Services AG
Secondary Sponsor(s)
Ethics review
Results
Results available:
Date Posted:
Date Completed:
URL:
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.6 - Version history